• Marked increases in Bet v 1 specific IgG4 were dose-dependent in 213 patients allergic to birch pollen

EPALINGES, Switzerland, March 1, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it will present new dose-ranging data on its lead-product AllerT at the AAAAI annual meeting. The annual meeting of the AAAAI (American Academy of Allergy, Asthma and Immunology) will take place in Atlanta, USA, from March 3 to 6, 2017.

The following scientific communication will be presented during the meeting:

Presentation Title: "Dose dependent increase of Bet v 1 specific IgG4 after Bet v 1 COP therapy"
Presenter: Alexander Kettner, Ph.D
Time and Date: Monday, March 6, 2017, 9.45 am-10.45 am
Session: 4210 ; Allergen Extracts and Other Forms of Immunotherapy
Poster #: 804
Location: Georgia World Congress Center, Level One, South Exhibit Hall B2

Abstract is available on the AAAAI meeting website: http://annualmeeting.aaaai.org

 

Contact

  • Biopôle III, Route de la Corniche 9B
    CH-1066 Epalinges
  • Email:
Top

This website uses cookies to ensure you get the best experience on our website.